Class / Patent application number | Description | Number of patent applications / Date published |
544014000 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos | 54 |
544031000 | Phenothiazine as three cyclos of polycyclo ring system having at least four cyclos | 1 |
20130053555 | ORGANIC ELECTROLUMINESCENT DEVICES - The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), and the corresponding compounds. | 02-28-2013 |
544032000 | Tricyclo ring system having the six-membered hetero ring as one of the cyclos | 26 |
544034000 | Plural ring nitrogens in the tricyclo ring system | 2 |
20090192308 | 1,5-DIHYDRO-2H-PYRROL-2-ONE TRICYCLIC DERIVATIVES HAVING ANTI-INFECTIVE ACTIVITY - Preparation of a new class of heterocyclic compounds pharmacologically active as anti-infectives, structurally correlated with 1,5-dihydro-2H-pyrrol-2-one. | 07-30-2009 |
20140200344 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS - Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (I | 07-17-2014 |
544035000 | Phenothiazines (including hydrogenated) | 24 |
20080200672 | Highly enantioselective carbonyl reduction with borane catalyzed by chiral spiroborate esters derived from chiral beta-aminoalcohols - Novel spiroborate esters derived from non-recemic 1,2-amino alcohols were examined as chiral catalyst in the borane reduction of acetophenone and other aromatic ketones at room temperature. The optically active alcohols were obtained in excellent chemical yields and up to 99% ee with less than 10% catalyst. | 08-21-2008 |
20090005557 | Electron-Conjugated Organic Silane Compound and Production Method Thereof - The present invention provides a π-electron-conjugated organice silane compound that give an organic thin film superior in peeling restance, orientation, crystallinity and eletroconductive properties, and a production method thereof. | 01-01-2009 |
20090259040 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis, etc., for example, a tauopathy; a disease of tau protein aggregation; Alzheimer's disease (AD); Pick's disease; Progressive Supranuclear Palsy (PSP); fronto temporal dementia (FTD); parkinsonism linked to chromosome 17 (FTDP-17); disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC); pallido-ponto-nigral degeneration (PPND); Guam-ALS syndrome; pallido-nigro-luysian degeneration (PNLD); cortico-basal degeneration (CBD); mild cognitive impairment (MCI); skin cancer; melanoma; methemoglobinemia; a viral infection; a bacterial infection; a protozoal infection; a parasitic infection; malaria; visceral leishmaniasis; African sleeping sickness; toxoplasmosis; giardiasis; Chagas' disease; Hepatitis C virus (HCV) infection; human immunodeficiency virus (HIV) infection; West Nile virus (WNV) infection; a synucleinopathy; Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); drug-induced parkinsonism; and pure autonomic failure (PAF). | 10-15-2009 |
20090306370 | Method Of Manufacturing An Organic Silicon Compound That Contains A Methacryloxy Group Or An Acryloxy Group - A method of manufacturing an organic silicon compound that contains a methacryloxy group or an acryloxy group, the method being characterized by the fact that manufacturing or conducting purification by distillation is carried out in the presence of a phenothiazine derivative having a molecular weight equal to or higher than 240. And a stable composition comprising an organic silicon compound that contains a methacryloxy group or an acryloxy group and a phenothiazine derivative having a molecular weight equal to or higher than 240 and used in an amount sufficient to stabilize the aforementioned organic silicon compound. | 12-10-2009 |
20100063276 | USE OF 10-[(3R)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE FOR THE PREPARATION OF A DRUG HAVING A SELECTIVE INHIBITION OF MUSCARINIC M1, M2, AND M3 RECEPTORS - This invention relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine as well as its pharmaceutically acceptable salts for the preparation of a drug having the particularity of treating or preventing urinary incontinence, by local and/or oral route. | 03-11-2010 |
20100190978 | METHYLENE BLUE - CURCUMIN ANALOG FOR THE TREATMENT OF ALZHEIMER'S DISEASE - A methylene blue-curcumin hybrid useful in treating Alzheimer's Disease. | 07-29-2010 |
20100204469 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF - Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity. | 08-12-2010 |
20100331540 | METHOD FOR PRODUCING COMPOUND HAVING DEUTERATED AROMATIC RING OR HETEROCYCLIC RING - A method for producing a compound having a deuterated aromatic ring or heterocyclic ring according to the invention includes heating a compound having an aromatic ring or heterocyclic ring in the presence of heavy water, a transition metal and a metal which generates deuterium. As the metal which generates deuterium, at least one metal selected from the group consisting of aluminum, magnesium, zinc, iron, lead and tin is preferred. As the transition metal, at least one metal selected from the group consisting of platinum, palladium, ruthenium and rhodium is preferred. The heating is preferably carried out by microwave irradiation. | 12-30-2010 |
20110028716 | Dye for a Dye-Sensitised Solar Cell, and a Solar Cell Comprising the Same - The present invention relates to a dye for a dye-sensitised solar cell. The dye according to the present invention has a high degree of light absorbency and can improve the photoelectric current conversion efficiency when employed in a light-absorbing layer for a solar cell. | 02-03-2011 |
20110288292 | MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES - The present invention relates to substituted benzo[c]phenanthrene derivatives and to the production and to the use thereof in electronic devices, and to the electronic devices themselves. The present invention relates in particular to benzo[c]phenanthrene derivatives substituted with at least one aromatic unit or at least one diarylamino unit. | 11-24-2011 |
20130324716 | HOLE TRANSPORT MATERIALS INCLUDING OLED APPLICATIONS - The composition described here comprises at least one hole-transporting compound, wherein the hole-transporting compound comprises a core covalently bonded to at least two arylamine groups, wherein the arylamine group optionally comprises one or more intractability groups. The composition can provide good film formation and stability when coated onto hole injection layers. Solution processing of hole transporting layers of OLEDs can be achieved with the composition described here. Good mobility can be achieved. | 12-05-2013 |
20140058099 | NOVEL COMPOUND, CHARGE TRANSPORT MATERIAL, AND ORGANIC DEVICE - The compounds represented fey the following general formula is is thermally stable and has excellent characteristics as a charge transport material [Ar | 02-27-2014 |
20160020409 | CHARGE TRANSPORT MATERIAL, HOST MATERIAL, THIN FILM AND ORGANIC LIGHT EMITTING ELEMENT - A compound represented by the following formula (1) is useful as a charge transporting material. R | 01-21-2016 |
544036000 | Purification or recovery | 3 |
20090171081 | Process of making 3-phenylimino-3h-phenothiazine or 3-phenylimino-3h-phenoxazine mediator - A method of forming a 3-phenylimino-3H-phenothiazine or a 3-phenylimino-3H-phenoxazine mediator includes providing a first reactant including phenothiazine or phenoxazine, providing a first solvent, providing a second reactant and providing a second solvent. The first reactant, first solvent, second reactant and second solvent are combined to form a reactants solution. Sodium persulfate is added to the reactants solution to couple the first and second reactants resulting in a reaction solution including the 3-phenylimino-3H-phenothiazine or the 3-phenylimino-3H-phenoxazine mediator. | 07-02-2009 |
20160200696 | PROCESS FOR THE PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS | 07-14-2016 |
20160251325 | METHODS OF CHEMICAL SYNTHESIS OF DIAMINOPHENOTHIAZINIUM COMPOUNDS INCLUDING METHYLTHIONINIUM CHLORIDE (MTC) | 09-01-2016 |
544037000 | Nitrogen bonded directly to phenothiazine ring system | 7 |
20110015391 | STABILIZER OF COLOR FORMER AND USE THEREOF - The present invention provides a stabilizer that can stabilize a salt of 10-(carboxymethylaminocarbonyn-3,7-bis(dimethylamino)phenothiazine or a derivative thereof even under the existence of moisture or under light irradiation. A compound described in at least one of (1) and (2) below is used as the stabilizer of the salt of 10-(carboxymethylaminocarbonyl)-3,7-bis(dimethylamino)phenothiazine or the derivative thereof.
| 01-20-2011 |
20130123491 | METHOD FOR PRESERVING AQUEOUS SOLUTION CONTAINING LEUCO CHROMOGEN - It is to provide a method for preserving an aqueous solution comprising a leuco chromogen, comprising adding at least one compound selected from the group consisting of polyoxyethylene alkylamine and polyoxyethylene alkenylamine to the aqueous solution containing a leuco chromogen, and a method for stabilizing a leuco chromogen, comprising allowing the leuco chromogen to coexist in an aqueous solution comprising at least one compound selected from the group consisting of polyoxyethylene alkylamine and polyoxyethylene alkenylamine. The present invention provides a method for preserving an aqueous solution comprising a leuco chromogen for stably preserving the leuco chromogen in an aqueous solution and a method for stabilizing a leuco chromogen. | 05-16-2013 |
20140114063 | ORGANIC ELECTROLUMINESCENCE MATERIAL AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME - An organic electroluminescence (EL) material and an organic EL device including the same, the organic electroluminescence (EL) material being represented by following Chemical Formula 1: | 04-24-2014 |
20140142300 | ORGANIC ELECTROLUMINESCENCE MATERIAL AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME - An organic electroluminescence (EL) material and an organic EL device, the organic EL material being represented by Formula 1, below: | 05-22-2014 |
20140155591 | ARYLAMINE COMPOUND AND ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME - An arylamine compound and an organic electroluminescence device, the compound being represented by following Formula 1: | 06-05-2014 |
20140235854 | Process for Preparing Diaminophenothiazinium Compounds - Process for preparing compounds of the diaminophenothiazinium type of formula (II) below. The products have a high degree of purity and are useful for the preparation of medicaments. | 08-21-2014 |
20150291542 | Antiviral Water-Soluble Product with Anti-HIV Effect, Based on Ionic Silver and Methylene Blue Compound; Method of Its Production and Examples of HIV-infected Patients' Treatment - A new antiviral water-soluble pharmacological product with anti-HIV effect, is based on ionic silver and methylene blue compound. The new substance is produced in the form of water-soluble powder that can be used for the preparation of finished dosage forms for treating viral infections, especially HIV infection. The product has a potential ability to radically suppress the infectious agents without leading to any mutations and resistance of viruses. The composition of the new product proposed under the conventional name Argothiazin-A™ corresponds to the chemical formula: C | 10-15-2015 |
544038000 | Carbon bonded directly to ring nitrogen of phenothiazine ring system | 1 |
20140155592 | ARYLAMINE COMPOUND AND ELECTROLUMINESCENCE DEVICE USING THE SAME - An arylamine compound is represented by Formula 1. | 06-05-2014 |
544047000 | Bicyclo ring system having the six-membered hetero ring as one of the cyclos | 27 |
20090118498 | OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS - A method for increasing ozone concentration in a liquid can include: providing a gas having ozone; introducing the ozone-containing gas into a liquid, wherein the liquid and ozone combination has a temperature between about 0.8 and about 1.5 times the critical temperature of ozone; and increasing isothermally, the pressure of the ozone-containing gas above the liquid to about 0.3 to about 5 times the critical pressure of ozone so as to increase the ozone concentration in the liquid. The temperature is expressed in absolute units (Kelvin or Rankin). The method can be used for removing ozone from a gas or for purifying ozone. The liquid having a high ozone concentration can be used for ozonolysis of a substrate. | 05-07-2009 |
20100063277 | Intramolecular C-H amination with sulfonyl azides - Cobalt (II) complexes of porphyrins are effective catalysts for intramolecular nitrene insertion of C—H bonds with arylsulfonyl azides. The cobalt-catalyzed process can proceed efficiently under mild and neutral conditions in low catalyst loading without the need of other reagents or additives, generating nitrogen gas as the only byproduct. Using the simple tetraphenylporphyrin (TPP) as the ligand, the cobalt-catalyzed intramolecular amidation can be applied to primary, secondary, and tertiary C—H bonds and suitable for a broad range of arylsulfonyl azides, leading to the syntheses of various benzosultam derivatives in excellent yields | 03-11-2010 |
20120309964 | CYCLIC AMINE COMPOUND AND ACARICIDE - The present invention provides a cyclic amine compound represented by formula (I) (in formula (I), Cy | 12-06-2012 |
20120323001 | BACE INHIBITORS - The present invention provides BACE inhibitors of Formula I: | 12-20-2012 |
20140121369 | METHOD FOR PURIFYING CEFTIZOXIME SODIUM - A novel process for refining Ceftizoxime sodium compound, comprises the steps of: 1) dissolving crude Ceftizoxime sodium in water, and extracting with cyclohexane or ethyl acetate, followed by separating the organic phase containing impurities, producing an aqueous phase containing Ceftizoxime sodium; 2) adding ammonia or ammonium hydroxide into the above aqueous phase while stirring, followed by filtrating the precipitate, producing an aqueous filtrate containing Ceftizoxime sodium; 3) adding an alcoholic solvent in the aqueous solution and recrystallizing under controlled temperature, followed by centrifuging and washing the resultant crystals, producing the refined Ceftizoxime sodium after drying; and 4) optionally returning the mother liquid of the recrystallization process to step 3). | 05-01-2014 |
20140121370 | NOVEL METHOD FOR PREPARING CEFMENOXIME HYDROCHLORIDE COMPOUND - A novel process for purifying Cefmenoxime hydrochloride comprises: 1) adding a solvent wherein Cefmenoxime hydrochloride is insoluble at the temperature less than 30° C. filtering after vigorous stirring, washing the filter cake with a solvent wherein Cefmenoxime hydrochloride is insoluble at a temperature less 20° C., and drying; 2) placing the filter cake into ammonium hydroxide, controlling the pH value less than 9 with a gentle agitation to obtain Cefmenoxime acid solution in ammonium hydroxide, and then filtering out the precipitate; 3) adding hydrochloric acid at a concentration of 0.5-4 mol/L to Cefmenoxime acid solution in ammonium hydroxide slowly and controlling the temperature between 30-60° C. and the final pH between 0.5-3.0, and then cooling down to a minimum of 10° C. and standing still to allow crystallization, filtrating and vacuum drying. | 05-01-2014 |
20150073138 | NOVEL PROCESS FOR PREPARING CEFTAROLINE FOSAMIL - The present invention relates to a novel process for preparing ceftaroline fosamil as well as to a intermediates of this process. | 03-12-2015 |
20150291619 | PROCESSES FOR PRODUCTION OF INTERMEDIATES FOR 2-ALKYL CEPHEM COMPOUNDS - The invention relates to processes for the production of intermediates for preparing 2-alkyl cephem compounds useful as antimicrobial drugs. The invention provides a process which comprises oxidating a compound of the formula (I) or a salt thereof to give a compound of the formula (II) or a salt thereof wherein each symbol is as defined in the specification. | 10-15-2015 |
544048000 | Three or more ring hetero atoms in the bicyclo ring system | 13 |
20090209755 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES - A compound represented by the general formula: | 08-20-2009 |
20100093999 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE - A compound represented by the general formula: | 04-15-2010 |
20100317850 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE - Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of Aβ or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for Aβ-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C | 12-16-2010 |
20110087022 | Dipeptidyl Peptidase Inhibitors - Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: | 04-14-2011 |
20110118462 | N-HETEROCYCLIC SUBSTITUENT-CONTAINING ANTIBIOTIC, PREPARATION AND USE THEREOF - The invention relates to N-heterocyclic substituent-containing antibiotics, their preparation, and their use. Disclosed are sodium and potassium salts of 7-(α-((N,N′-diisopropylamidino)thio)acetylamino)-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl) cephalosporanic acid as presented by the general structure (I), their preparation, and their use. The antibiotics of the invention can be used to treat diseases caused by Gram-positive or Gram-negative bacteria such as septicaemia, gastrointestinal tract infection, and urinary tract infection. They have increased half-life in blood and lowered toxicity. They can reduce the frequency of drug use and lower medical treatment costs. They have improved stability and can be stored at ambient temperatures. The method of the invention is simple, and it produces high purity products which can meet the requirements of clinical use. | 05-19-2011 |
20120095219 | PROCESS FOR PREPARING BRINZOLAMIDE - The present invention refers to the preparation and purification of brinzolamide as well as to novel compounds useful in such processes. | 04-19-2012 |
20120190848 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF FUSED AMINODIHYDROTHIAZINE DERIVATIVES - Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme. | 07-26-2012 |
20120214990 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION - A nitrogen-containing heterocyclic compound or pharmaceutically acceptable salt thereof represented by the general formula: | 08-23-2012 |
20120226035 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF - Disclosed is a compound represented by the general formula: | 09-06-2012 |
20120245345 | TRICYCLIC ANTIBIOTICS - Compound of formula (I): wherein A1 represents —O—, —S— or —N—R3; A2 represents —CH | 09-27-2012 |
20140235855 | Tricyclic Antibiotics - Compounds of formula (I), wherein A1 represents —O—, —S— or —CH | 08-21-2014 |
20140256933 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides compounds of Formula I: | 09-11-2014 |
20140350245 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides a compound of Formula I: | 11-27-2014 |
544049000 | Benzothiazines (including hydrogenated) | 6 |
20170231914 | A method and a device for producing nanoparticles | 08-17-2017 |
544051000 | 1,4-benzothiazines | 5 |
20090318687 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds - The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms. | 12-24-2009 |
20100168418 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF - A nitrogen-containing heterocyclic compound represented by the general formula: wherein the dashed line represents a single bond or a double bond; R | 07-01-2010 |
20110040089 | PROCESS FOR PREPARING BENZOMORPHOLINE DERIVATIVES BY HYDROGENATING O-NITROPHENOXY CARBONYL COMPOUNDS - A process for preparing benzomorpholine derivatives is described, in which an o-nitrophenoxy carbonyl compound is hydrogenated in the presence of extraneous metal-doped sponge metal catalysts based on nickel or cobalt with ring formation. | 02-17-2011 |
20120253039 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds - The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms. | 10-04-2012 |
20140330007 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES - The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. | 11-06-2014 |